SCHEMBL3301871

SCHEMBL3301871

CC(=O)N1CCC(c2nc3c(C#N)c(C)c(-c4ccccc4)c(N4CC[C@H](N(C)C)C4)c3o2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.37
MCHR1 Q99705 3/20 0.34
HTR1D P28221 2/20 0.34
HTR3A P46098 2/20 0.34
HTR6 P50406 2/20 0.34
TMEM97 Q5BJF2 2/20 0.34
MAPK8 P45983 2/20 0.34
BTK Q06187 2/20 0.34
MRGPRX2 Q96LB1 2/20 0.34
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
HTR1B P28222 1/20 0.34
SLC6A3 Q01959 1/20 0.34
ADRA1B P35368 1/20 0.34
MAPK10 P53779 1/20 0.34
HTR2B P41595 1/20 0.33
GAA P10253 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301498 0.91 HTR1D (0.38) MCHR1HTR1DHTR3AHTR6TMEM97
SCHEMBL3297857 0.90 HTR1D (0.37) MCHR1HTR1DHTR3AHTR6TMEM97
SCHEMBL3297965 0.86 HRH3 (0.35) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL3295925 0.86 USP30 (0.36) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL3294083 0.85 RXRA (0.38) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL3294079 0.85 RXRA (0.38) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL3295299 0.85 MCHR1 (0.36) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL4850672 0.84 MCHR1 (0.34) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL4850666 0.84 MCHR1 (0.34) HRH3MCHR1HTR1DHTR3AHTR6
SCHEMBL4797396 0.83 HTR1D (0.40) MCHR1HTR1DHTR3AHTR6TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737166-B2 Antifungal bicyclic hetero ring compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-06-15 US disclosed
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1932837-A1 BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION Daiichi Sankyo Company, Limited (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides CTPS1, TPP1, STS HRH3 4346/4885MCHR1 4162/4885HTR1D 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.